Key Insights

Highlights

Success Rate

84% trial completion

Published Results

37 trials with published results (11%)

Research Maturity

161 completed trials (48% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

9.0%

30 terminated out of 334 trials

Success Rate

84.3%

-2.2% vs benchmark

Late-Stage Pipeline

7%

24 trials in Phase 3/4

Results Transparency

23%

37 of 161 completed with results

Key Signals

37 with results84% success30 terminated

Data Visualizations

Phase Distribution

232Total
Not Applicable (95)
Early P 1 (3)
P 1 (37)
P 2 (73)
P 3 (16)
P 4 (8)

Trial Status

Completed161
Unknown73
Recruiting31
Terminated30
Active Not Recruiting14
Not Yet Recruiting13

Trial Success Rate

84.3%

Benchmark: 86.5%

Based on 161 completed trials

Clinical Trials (334)

Showing 20 of 20 trials
NCT07632703Not ApplicableNot Yet RecruitingPrimary

Construction and Feasibility Study of a Home-Based Intelligent Symptom Management Program for Lung Cancer Patients Receiving Combined Drug Therapy Based on Symptom Journey Profiling

NCT07489066Phase 2Recruiting

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

NCT06885697Phase 1Recruiting

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT07476287Phase 2Recruiting

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

NCT06494241Active Not Recruiting

Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study

NCT01687647Phase 3TerminatedPrimary

Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure

NCT02688036Phase 3Completed

Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC

NCT07143110RecruitingPrimary

LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada

NCT07588347Not ApplicableNot Yet RecruitingPrimary

Construction and Preliminary Evaluation of Dyadic Acceptance and Commitment Therapy for Couples With Fear of Lung Cancer Recurrence

NCT06376084Active Not Recruiting

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

NCT00534690Not ApplicableCompletedPrimary

Does PEP Compensate the Reduction of Tidal Volume During One Lung Ventilation?

NCT07590947Completed

Evaluation of the Utility of Rapid On-site Cytology Performed by an Interventional Pulmonologist During EBUS-TBNA.

NCT04380636Phase 3Active Not RecruitingPrimary

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

NCT05512377Phase 2Terminated

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

NCT07109154RecruitingPrimary

DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns

NCT07436598Recruiting

3D Virtual Resection for Predicting Lung Function in VATS

NCT05231278Not ApplicableCompletedPrimary

Confocal Laser Endomicroscopy Nodule Localization by Robotic Bronchoscopy

NCT07581379Active Not RecruitingPrimary

Advancing Precision Lung Cancer Surveillance and Outcomes in Diverse Populations

NCT03607539Phase 3CompletedPrimary

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

NCT07573748Not ApplicableNot Yet RecruitingPrimary

Apple Vision Pro-Assisted Vascular Identification in Lung Surgery

Scroll to load more

Research Network

Activity Timeline